Idiopathic pulmonary fibrosis
Last updated 18 Aug 2020
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
Idiopathic pulmonary fibrosis is a chronic, progressive lung disease. This condition causes scar tissue (fibrosis) to build up in the lungs, which makes the lungs unable to transport oxygen into the bloodstream effectively. The disease usually affects people between the ages of 50 and 70. Idiopathic pulmonary fibrosis belongs to a group of conditions called interstitial lung diseases (also known as ILD), which describes lung diseases that involve inflammation or scarring in the lung.
Video picks for Genetic conditionsVideo library
Description
Idiopathic pulmonary fibrosis is a chronic, progressive lung disease. This condition causes scar tissue (fibrosis) to build up in the lungs, which makes the lungs unable to transport oxygen into the bloodstream effectively. The disease usually affects people between the ages of 50 and 70. Idiopathic pulmonary fibrosis belongs to a group of conditions called interstitial lung diseases (also known as ILD), which describes lung diseases that involve inflammation or scarring in the lung.
The most common signs and symptoms of idiopathic pulmonary fibrosis are shortness of breath and a persistent dry, hacking cough. Many affected individuals also experience a loss of appetite and gradual weight loss. Some people with idiopathic pulmonary fibrosis develop widened and rounded tips of the fingers and toes (clubbing) resulting from a shortage of oxygen. These features are relatively nonspecific; not everyone with these health problems has idiopathic pulmonary fibrosis. Other respiratory diseases, some of which are less serious, can cause similar signs and symptoms.
In people with idiopathic pulmonary fibrosis, scarring of the lungs increases over time until the lungs can no longer provide enough oxygen to the body's organs and tissues. Some people with idiopathic pulmonary fibrosis develop other serious lung conditions, including lung cancer, blood clots in the lungs (pulmonary emboli), pneumonia, or high blood pressure in the blood vessels that supply the lungs (pulmonary hypertension). Most affected individuals survive 3 to 5 years after their diagnosis. However, the course of the disease is highly variable; some affected people become seriously ill within a few months, while others may live with the disease for a decade or longer.
In most cases, idiopathic pulmonary fibrosis occurs in only one person in a family. These cases are described as sporadic. However, a small percentage of people with this disease have at least one other affected family member. When idiopathic pulmonary fibrosis occurs in multiple members of the same family, it is known as familial pulmonary fibrosis.
Inheritance patterns
The source lists the following possible inheritance patterns: Autosomal dominant. More than one pattern can apply in different cases.
Related genes
Other names
Cryptogenic fibrosing alveolitis
Idiopathic fibrosing alveolitis, chronic form
IPF
Usual interstitial pneumonia
Patient picks for Genetic conditions

Chest and lungs
Pulmonary fibrosis
Pulmonary fibrosis is a serious lung disease where the tiny air sacs of the lungs (the alveoli) and the lung tissue next to the alveoli become damaged and scarred, resulting in lung fibrosis. The main symptom is shortness of breath that gradually gets worse. The cause is often not known but pulmonary fibrosis can be caused by a variety of underlying conditions. Treatments include treating any underlying cause in addition to steroids and other medicines. Increasingly lung transplantation may be considered.
by Dr Toni Hazell, FRCGP

Chest and lungs
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is a long-term condition of the lungs where the flow of air to the lungs is obstructed. Symptoms include cough and breathlessness. The condition is most often caused by smoking and the most important treatment is to stop smoking. Inhalers are commonly used to ease symptoms. Other treatments such as steroids, antibiotics, oxygen, and mucus-thinning (mucolytic) medicines are sometimes prescribed in more severe cases, or during a flare-up (exacerbation) of symptoms.
by Dr Toni Hazell, FRCGP

Children's health
Cystic fibrosis
Cystic fibrosis is an inherited disease which mainly affects the lungs and pancreas but can involve other organs. Symptoms usually begin in early childhood and include persistent cough, wheeze, repeated chest infections, difficulty digesting food and general ill health. Treatments include antibiotics, physiotherapy, medicines for thinning mucus, pancreatic enzyme replacements and other therapies.
by Dr Toni Hazell, FRCGP

Children's health
Congenital pulmonary airway malformation
Congenital pulmonary airway malformation (CPAM) is a rare abnormality of lung development. It is found either in unborn babies or in young babies. The name has recently changed from congenital cystic adenomatoid malformation (CCAM). It is increasingly detected by the routine ultrasound scan during pregnancy. Congenital means present from birth. Pulmonary means related to the lungs. The severity of the abnormality is very variable. Some lesions can shrink or even disappear without treatment. Some lesions cause the baby to have breathing problems very soon after birth. Some lesions cause severe problems for the baby and may have a poor outcome.
by Dr Hayley Willacy, FRCGP

Medicine
Ambrisentan for pulmonary hypertension
Ambrisentan is used to treat high blood pressure in people who have pulmonary arterial hypertension. The usual dose is one 5 mg tablet daily. You can take ambrisentan either with or without food. The most common side-effects are headache, and swollen feet and ankles.
by Michael Stewart, MRPharmS

Signs and symptoms
Idiopathic oedema
Idiopathic oedema is the term for fluid retention which it not caused by a known medical condition. It is most common in women and can sometimes worsen as you get older. Although there is no cure for idiopathic oedema, having a healthy diet which is low in salt can make a real difference. Support stockings and regular exercise are also beneficial.
by Dr Colin Tidy, MRCGP
Related patient information and medicines

Patient information leaflet
Pulmonary fibrosis
Pulmonary fibrosis is a serious lung disease where the tiny air sacs of the lungs (the alveoli) and the lung tissue next to the alveoli become damaged and scarred, resulting in lung fibrosis. The main symptom is shortness of breath that gradually gets worse. Pulmonary fibrosis causes The main causes of pulmonary fibrosis are: Unknown (called.

Patient information leaflet
Chronic persistent cough in adults
Usually symptom... Occasionally there can be a cough. Pulmonary fibrosis Pulmonary fibrosis. This is caused by damage and scarring of lung tissue, which causes cough and breathlessness. For more information on these conditions, follow the links where available. Will the cause of a persistent cough always be found. Sometimes you can be left with an.

Patient information leaflet
Pneumothorax
A pneumothorax is sometimes called a "collapsed lung" and it describes the condition in which air has become trapped next to a lung. Many cases occur without warning, particularly in healthy young men. Sarcoidosis Sarcoidosis. Cystic fibrosis Cystic fibrosis. Lung cancer Lung cancer. Idiopathic pulmonary fibrosis Pulmonary fibrosis. Other causes.

Patient information leaflet
Loss of appetite
If it is difficult to breathe, it may... Medical conditions causing this might include chronic obstructive pulmonary disease (COPD) Chronic obstructive pulmonary disease , pneumonia Pneumonia , asthma Asthma , pulmonary embolus Pulmonary embolism , and congestive heart failure Heart failure. Acid reflux Acid reflux and oesophagitis and indigestion.

Patient information leaflet
Gallium scan
A gallium scan uses a radioactive chemical to help create pictures which can show areas of possible infection, injury, inflammation or cancer. It does this by looking for areas where there is rapid ce... The image below shows how sarcoidosis Sarcoidosis may be diagnosed by gallium scan. Monitor the response to antibiotic treatment Antibiotics..

Patient information leaflet
Respiratory failure
Respiratory failure occurs when the breathing system fails to keep adequate blood oxygen levels. There may also be difficulties in removing waste gases, mainly blood carbon dioxide. Why does respiratory failure occur. Causes of respiratory failure Common causes of type I respiratory failure Chronic obstructive pulmonary disease... Pneumonia.
Further reading and references
- Idiopathic pulmonary fibrosis; MedlinePlus, National Library of Medicine.
- Allen RJ, Guillen-Guio B, Oldham JM, Ma SF, Dressen A, Paynton ML, Kraven LM, Obeidat M, Li X, Ng M, Braybrooke R, Molina-Molina M, Hobbs BD, Putman RK, Sakornsakolpat P, Booth HL, Fahy WA, Hart SP, Hill MR, Hirani N, Hubbard RB, McAnulty RJ, Millar AB, Navaratnam V, Oballa E, Parfrey H, Saini G, Whyte MKB, Zhang Y, Kaminski N, Adegunsoye A, Strek ME, Neighbors M, Sheng XR, Gudmundsson G, Gudnason V, Hatabu H, Lederer DJ, Manichaikul A, Newell JD Jr, O'Connor GT, Ortega VE, Xu H, Fingerlin TE, Bosse Y, Hao K, Joubert P, Nickle DC, Sin DD, Timens W, Furniss D, Morris AP, Zondervan KT, Hall IP, Sayers I, Tobin MD, Maher TM, Cho MH, Hunninghake GM, Schwartz DA, Yaspan BL, Molyneaux PL, Flores C, Noth I, Jenkins RG, Wain LV. Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2020 Mar 1;201(5):564-574. doi: 10.1164/rccm.201905-1017OC.
- Allen RJ, Porte J, Braybrooke R, Flores C, Fingerlin TE, Oldham JM, Guillen-Guio B, Ma SF, Okamoto T, John AE, Obeidat M, Yang IV, Henry A, Hubbard RB, Navaratnam V, Saini G, Thompson N, Booth HL, Hart SP, Hill MR, Hirani N, Maher TM, McAnulty RJ, Millar AB, Molyneaux PL, Parfrey H, Rassl DM, Whyte MKB, Fahy WA, Marshall RP, Oballa E, Bosse Y, Nickle DC, Sin DD, Timens W, Shrine N, Sayers I, Hall IP, Noth I, Schwartz DA, Tobin MD, Wain LV, Jenkins RG. Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. Lancet Respir Med. 2017 Nov;5(11):869-880. doi: 10.1016/S2213-2600(17)30387-9. Epub 2017 Oct 20.
- American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):646-64. doi: 10.1164/ajrccm.161.2.ats3-00. No abstract available.
- Arish N, Petukhov D, Wallach-Dayan SB. The Role of Telomerase and Telomeres in Interstitial Lung Diseases: From Molecules to Clinical Implications. Int J Mol Sci. 2019 Jun 19;20(12):2996. doi: 10.3390/ijms20122996.
- Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, Markin C, Lawson WE, Xie M, Vulto I, Phillips JA 3rd, Lansdorp PM, Greider CW, Loyd JE. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med. 2007 Mar 29;356(13):1317-26. doi: 10.1056/NEJMoa066157.
- Borchers AT, Chang C, Keen CL, Gershwin ME. Idiopathic pulmonary fibrosis-an epidemiological and pathological review. Clin Rev Allergy Immunol. 2011 Apr;40(2):117-34. doi: 10.1007/s12016-010-8211-5.
- Garcia CK, Talbert JL. Pulmonary Fibrosis Predisposition Overview. 2005 Jan 21 [updated 2025 Dec 4]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK1230/
- Harari S, Caminati A. IPF: new insight on pathogenesis and treatment. Allergy. 2010 May;65(5):537-53. doi: 10.1111/j.1398-9995.2009.02305.x. Epub 2010 Feb 1.
- Hobbs BD, Putman RK, Araki T, Nishino M, Gudmundsson G, Gudnason V, Eiriksdottir G, Zilhao Nogueira NR, Dupuis J, Xu H, O'Connor GT, Manichaikul A, Nguyen J, Podolanczuk AJ, Madahar P, Rotter JI, Lederer DJ, Barr RG, Rich SS, Ampleford EJ, Ortega VE, Peters SP, O'Neal WK, Newell JD Jr, Bleecker ER, Meyers DA, Allen RJ, Oldham JM, Ma SF, Noth I, Jenkins RG, Maher TM, Hubbard RB, Wain LV, Fingerlin TE, Schwartz DA, Washko GR, Rosas IO, Silverman EK, Hatabu H, Cho MH, Hunninghake GM. Overlap of Genetic Risk between Interstitial Lung Abnormalities and Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2019 Dec 1;200(11):1402-1413. doi: 10.1164/rccm.201903-0511OC.
- Kolb M, Vasakova M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res. 2019 Mar 14;20(1):57. doi: 10.1186/s12931-019-1022-1.
- McLean-Tooke A, Moore I, Lake F. Idiopathic and immune-related pulmonary fibrosis: diagnostic and therapeutic challenges. Clin Transl Immunology. 2019 Nov 5;8(11):e1086. doi: 10.1002/cti2.1086. eCollection 2019.
- Ryu JH, Moua T, Daniels CE, Hartman TE, Yi ES, Utz JP, Limper AH. Idiopathic pulmonary fibrosis: evolving concepts. Mayo Clin Proc. 2014 Aug;89(8):1130-42. doi: 10.1016/j.mayocp.2014.03.016. Epub 2014 May 24.
- Stuart BD, Lee JS, Kozlitina J, Noth I, Devine MS, Glazer CS, Torres F, Kaza V, Girod CE, Jones KD, Elicker BM, Ma SF, Vij R, Collard HR, Wolters PJ, Garcia CK. Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. Lancet Respir Med. 2014 Jul;2(7):557-65. doi: 10.1016/S2213-2600(14)70124-9. Epub 2014 Jun 16.
- Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, Weissler JC, Rosenblatt RL, Shay JW, Garcia CK. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A. 2007 May 1;104(18):7552-7. doi: 10.1073/pnas.0701009104. Epub 2007 Apr 25.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

